Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148808 · ClinicalTrials.gov registry record · Phase 1
Natural Vascular Scaffold (NVS) Therapy
A Phase 1 study, sponsored by Alucent Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03148808: Completed Phase 1 study, sponsored by Alucent Biomedical.
NCT03148808 is a Phase 1 study that has completed, run by Alucent Biomedical. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03148808, a Phase 1 study, has completed, sponsored by Alucent Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The NVS Therapy is being studied to evaluate the safety and efficacy of retention of acute luminal gain, leading to acute hemodynamic improvement in superficial femoral and popliteal arteries with reference vessel diameters between 3.5 and 7.0 mm and lesion lengths between 36 and 96mm. The system is intended for use in patients with de novo lesions in the superficial femoral and proximal popliteal arteries.
Primary Outcome
The overall composite occurrence of participants free from from all-cause mortality, target limb major amputation, and target lesion revascularization through post-index procedure to Day 30 will be summarized as a percentage.
Interventions
- COMBINATION_PRODUCT NVS Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 1 |
What the finished NCT03148808 record still lists
NCT03148808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which NVS Therapy is the first listed.
NCT03148808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03148808 about?
NCT03148808 is a clinical study titled "Natural Vascular Scaffold (NVS) Therapy". The NVS Therapy is being studied to evaluate the safety and efficacy of retention of acute luminal gain, leading to acute hemodynamic improvement in superficial femoral and popliteal arteries with reference vessel diameters between 3.5 and 7.0 mm and lesion lengths between 36 and 96mm. The system is...
What is the current status of trial NCT03148808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-05-25. Estimated completion is 2018-10-29.
What interventions are being tested in trial NCT03148808?
The interventions under investigation include: NVS Therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03148808?
This trial is sponsored by Alucent Biomedical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03148808's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI